|
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) |
|
LXRX's Market share relative to its competitors, as of Q1 2025
As of Q1 2025 (Revenue in Millions of $)
Date modified: 2025-07-14T21:20:56+00:00
|
Select the Relationship:
|
|
Select the Category:
|
|
| COMPANY NAME |
REVENUES
12 Months Ending
Q1 2025 |
MARKET SHARE
12 Months
Q1 2025 |
MARKET SHARE
MRQ
Q1 2025 |
MARKET SHARE
A Quarter Before
Q4 2024 |
| Lexicon Pharmaceuticals Inc |
31.21 |
0.00% |
0.00 % |
0.02 % |
| Johnson and Johnson |
89,331.00 |
13.70% |
13.58% |
13.43% |
| Merck and Co Inc |
63,922.00 |
9.80% |
9.63% |
9.32% |
| Abbvie Inc |
57,367.00 |
8.80% |
8.28% |
9.01% |
| Sanofi |
49,599.72 |
7.61% |
7.61% |
0.00% |
| Eli Lilly And Company |
49,003.20 |
7.51% |
7.89% |
8.07% |
| Bristol myers Squibb Company |
47,636.00 |
7.30% |
6.95% |
7.36% |
| Novartis Ag |
46,660.00 |
7.15% |
7.15% |
0.00% |
| Astrazeneca Plc |
45,811.00 |
7.02% |
7.02% |
0.00% |
| Amgen Inc |
33,424.00 |
5.13% |
5.64% |
5.07% |
| Takeda Pharmaceutical Company Limited |
29,166.69 |
4.47% |
4.47% |
0.00% |
| Gilead Sciences Inc |
28,735.00 |
4.41% |
4.13% |
4.51% |
| Teva Pharmaceutical Industries Limited |
16,617.00 |
2.55% |
2.41% |
2.52% |
| Viatris Inc |
14,330.20 |
2.20% |
2.02% |
2.10% |
| Regeneron Pharmaceuticals Inc |
14,085.70 |
2.16% |
1.88% |
2.26% |
| Vertex Pharmaceuticals Inc |
11,099.70 |
1.70% |
1.72% |
1.74% |
| Biogen Inc |
9,816.40 |
1.51% |
1.51% |
1.46% |
| Bausch Health Companies Inc |
9,731.00 |
1.49% |
1.40% |
1.53% |
| Organon and Co |
6,294.00 |
0.97% |
0.94% |
0.95% |
| Jazz Pharmaceuticals Plc |
4,064.81 |
0.62% |
0.56% |
0.65% |
| Horizon Therapeutics Public Limited Company |
3,643.45 |
0.56% |
0.59% |
0.50% |
| United Therapeutics Corporation |
2,994.10 |
0.46% |
0.49% |
0.44% |
| Biomarin Pharmaceutical Inc |
2,950.23 |
0.45% |
0.46% |
0.45% |
| Alnylam Pharmaceuticals Inc |
2,348.10 |
0.36% |
0.37% |
0.35% |
| Royalty Pharma Plc |
2,263.85 |
0.35% |
0.35% |
0.35% |
| Sarepta Therapeutics Inc |
2,233.37 |
0.34% |
0.46% |
0.39% |
| Ionis Pharmaceuticals Inc |
941.14 |
0.14% |
0.08% |
0.19% |
| Biohaven Ltd |
859.68 |
0.13% |
0.00% |
0.00% |
| Apellis Pharmaceuticals Inc |
775.84 |
0.12% |
0.10% |
0.13% |
| Kiniksa Pharmaceuticals International Plc |
481.17 |
0.07% |
0.09% |
0.07% |
| Iteos Therapeutics Inc |
454.23 |
0.07% |
0.00% |
0.00% |
| Axsome Therapeutics Inc |
449.36 |
0.07% |
0.08% |
0.10% |
| Arvinas Inc |
426.90 |
0.07% |
0.12% |
0.04% |
| Innoviva Inc |
408.35 |
0.06% |
0.05% |
0.05% |
| Myovant Sciences Ltd |
379.11 |
0.06% |
0.06% |
0.06% |
| Ardelyx inc |
361.71 |
0.06% |
0.05% |
0.07% |
| Mannkind Corporation |
297.60 |
0.05% |
0.05% |
0.05% |
| Legend Biotech Corporation |
285.14 |
0.04% |
0.04% |
0.00% |
| Arrowhead Pharmaceuticals Inc |
278.34 |
0.04% |
0.34% |
0.00% |
| Travere Therapeutics Inc |
273.53 |
0.04% |
0.05% |
0.04% |
| Galapagos Nv |
268.49 |
0.04% |
0.04% |
0.00% |
| Morphosys Ag |
266.87 |
0.04% |
0.04% |
0.00% |
| Esperion Therapeutics Inc |
259.57 |
0.04% |
0.04% |
0.04% |
| Pharming Group N v |
245.10 |
0.04% |
0.00% |
0.12% |
| Puma Biotechnology Inc |
232.71 |
0.04% |
0.03% |
0.04% |
| Stoke Therapeutics Inc |
190.91 |
0.03% |
0.10% |
0.01% |
| Bridgebio Pharma Inc |
127.42 |
0.02% |
0.07% |
0.00% |
| Nektar Therapeutics |
87.25 |
0.01% |
0.01% |
0.02% |
| Morphic Holding inc |
75.30 |
0.01% |
0.00% |
0.00% |
| Journey Medical Corp |
56.24 |
0.01% |
0.01% |
0.01% |
| Aquestive Therapeutics Inc |
54.23 |
0.01% |
0.01% |
0.01% |
| Spero Therapeutics Inc |
44.58 |
0.01% |
0.00% |
0.01% |
| Xoma Royalty Corporation |
42.91 |
0.01% |
0.01% |
0.01% |
| Scpharmaceuticals Inc |
41.98 |
0.01% |
0.01% |
0.01% |
| Mirati Therapeutics Inc |
38.19 |
0.01% |
0.01% |
0.01% |
| Agios Pharmaceuticals Inc |
36.50 |
0.01% |
0.01% |
0.01% |
| Mereo Biopharma Group Plc |
36.46 |
0.01% |
0.00% |
0.00% |
| Casi Pharmaceuticals inc |
28.54 |
0.00% |
0.00% |
0.00% |
| Bicycle Therapeutics Plc |
25.72 |
0.00% |
0.01% |
0.00% |
| Silence Therapeutics Plc |
25.06 |
0.00% |
0.00% |
0.03% |
| Allarity Therapeutics Inc |
23.79 |
0.00% |
0.00% |
0.00% |
| Avalo Therapeutics Inc |
17.38 |
0.00% |
0.00% |
0.00% |
| Medicure Inc |
16.78 |
0.00% |
0.00% |
0.00% |
| Iterum Therapeutics Plc |
14.32 |
0.00% |
0.00% |
0.00% |
| Xenon Pharmaceuticals Inc |
13.17 |
0.00% |
0.00% |
0.00% |
| Kalvista Pharmaceuticals Inc |
12.69 |
0.00% |
0.00% |
0.00% |
| Xilio Therapeutics inc |
9.27 |
0.00% |
0.00% |
0.00% |
| Dianthus Therapeutics Inc |
6.52 |
0.00% |
0.00% |
0.00% |
| Ngm Biopharmaceuticals Inc |
4.42 |
0.00% |
0.00% |
0.00% |
| Infinity Pharmaceuticals Inc |
2.57 |
0.00% |
0.00% |
0.00% |
| Aptinyx Inc |
1.75 |
0.00% |
0.00% |
0.00% |
| Immuron Limited |
1.48 |
0.00% |
0.00% |
0.00% |
| Therapeuticsmd Inc |
1.41 |
0.00% |
0.00% |
0.00% |
| Xortx Therapeutics inc |
0.92 |
0.00% |
0.00% |
0.00% |
| Timber Pharmaceuticals Inc |
0.88 |
0.00% |
0.00% |
0.00% |
| Inflarx N v |
0.07 |
0.00% |
0.00% |
0.00% |
| Regulus Therapeutics Inc |
0.06 |
0.00% |
0.00% |
0.00% |
| Benitec Biopharma Inc |
0.06 |
0.00% |
0.00% |
0.00% |
| Nascent Biotech Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Acer Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Edgewise Therapeutics inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Evelo Biosciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Transcode Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Atea Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Medicinova Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Xtl Biopharmaceuticals Ltd |
0.00 |
0.00% |
0.00% |
0.00% |
| Biovie Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Vera Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Astria Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Dice Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Ventyx Biosciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Prelude Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Eqrx Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Beigene Ltd |
0.00 |
0.00% |
0.69% |
0.00% |
| Azitra Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Acelyrin Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Nexien Biopharma Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Protokinetix Incorporated |
0.00 |
0.00% |
0.00% |
0.00% |
| Viracta Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Biophytis Sa |
0.00 |
0.00% |
0.00% |
0.00% |
| Galecto Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Protagenic Therapeutics Inc new |
0.00 |
0.00% |
0.00% |
0.00% |
| Satsuma Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Nanoviricides inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Connect Biopharma Holdings Limited |
0.00 |
0.00% |
0.00% |
0.02% |
| Calcimedica Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Cellectar Biosciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Edesa Biotech Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Mineralys Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Grifols Sa |
0.00 |
0.00% |
0.00% |
0.00% |
| Arrivent Biopharma inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Contineum Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Os Therapies Incoporated |
0.00 |
0.00% |
0.00% |
0.00% |
| Biostax Corp |
0.00 |
0.00% |
0.00% |
0.00% |
| SUBTOTAL |
652,142.40 |
100% |
161,235.14 |
100% |
LXRX's Market share relative to its competitors, as of Q1 2025 within the Major Pharmaceutical Preparations Industry
As of Q1 2025
LXRX's Market share relative to its competitors, as of Q1 2025 within the Healthcare Sector
As of Q1 2025
Note: Market share is calculated based on total revenue. To get a more accurate picture of Lexicon Pharmaceuticals Inc's market divisions, geographic dispersion, segments, products, and services, visit Lexicon Pharmaceuticals Inc's Business Segment. The list includes publicly traded companies only. More information about the sources of this report can be found here. |
